Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test
June 21, 2011
Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test
Transgenomics' CEO said these first forays into next-gen sequencing don't represent a shift in the company's strategy, which has so far been focused on Sanger sequencing and PCR technologies for molecular diagnostics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Analyst Says Sequencing-Based Dx Could Be 'Ultimate Opportunity' for Illumina
June 8, 2011 / Clinical Sequencing News - Q&A: Matt Posard on Illumina's Clinically Focused Business Unit
March 14, 2012 / Clinical Sequencing News - NIPT and Cancer Drive Illumina's Clinical Business in Q1 as it Looks to Launch Fetal Aneuploidy IVD
April 24, 2013 / Clinical Sequencing News - Analysts Increase Valuations, Upgrade Illumina
January 4, 2013 / GenomeWeb Daily News - Oxford Group Launches PGM-Based Cancer Test under UK's Stratified Medicine Program
January 2, 2013 / Clinical Sequencing News